Zhewitra is a Sunrise Remedies-linked foreign-market vardenafil brand family. Unlike a single narrowly defined tablet product, its public material references regular Zhewitra, an oral jelly presentation, soft-form naming and vardenafil–dapoxetine combination variants. Those differences are the core of understanding the brand accurately.
Sunrise’s main Zhewitra product page lists vardenafil strengths including 10 mg and 20 mg alongside higher numbers, but the same page labels its dosage form as oral jelly while discussing conventional tablets elsewhere. The separate Zhewitra Oral Jelly entry specifically describes a 20 mg jelly. That inconsistency means the broad family page cannot serve as independent proof of the form of every Zhewitra SKU.
This article examines the identifiable forms and reported ingredients without turning foreign product marketing into a U.S. purchasing offer. For the full directory, see Indian vardenafil brands; for separately FDA-approved U.S. products, see the generic vardenafil guide.
Sunrise Remedies presents Zhewitra products under an ED and premature-ejaculation product category and describes itself as their manufacturer or supplier. This is stronger evidence of a corporate product-line claim than a reseller-only advertisement, but source-specific package identity and company roles remain relevant for each formulation.
Sunrise’s own records are not perfectly consistent: its top-level Zhewitra listing mentions multiple strengths and labels the form as oral jelly, while the explanatory content also speaks of tablets. Instead of quietly reconciling those conflicts, editorial coverage should distinguish the broad company catalogue from individually documented product pages.
The variant name is substantive evidence because it can change the dosage form or active ingredients. The table reports product-line descriptions without treating different products as medically interchangeable or granting U.S. approval.
Entries claiming higher doses or a second drug are not appropriate as U.S. dosing advice. The approved U.S. film-coated vardenafil strengths are a different product record.
| Named Sunrise listing | Reported composition/form | Interpretation |
|---|---|---|
| Zhewitra core family | Vardenafil listings at 10, 20 and higher claimed strengths | Main listing has contradictory dosage-form description |
| Zhewitra Oral Jelly | Vardenafil 20 mg oral jelly in a separate listing | Distinct foreign dosage form; not U.S. ODT |
| Zhewitrasoft | Vardenafil 20 mg soft-form name | Form identity and package should be verified |
| Super Zhewitra | Vardenafil 20 mg plus dapoxetine 60 mg | Combination product, not plain vardenafil |
| Extra Super Zhewitra | Sunrise narrative states vardenafil 40 mg + dapoxetine 60 mg | Separate higher-strength combination claim; not a U.S. regimen |
| U.S. approved generic | Separate labeled vardenafil product | No FDA approval transfers from ingredient to brand |
Sunrise separately lists Super Zhewitra as a combination of vardenafil 20 mg and dapoxetine 60 mg, adding a second pharmacologically active ingredient. Dapoxetine is an SSRI-class drug used in some markets in products promoted for premature ejaculation; the combination cannot be described as an ordinary vardenafil tablet.
Sunrise’s broader Zhewitra page also describes Extra Super Zhewitra as vardenafil 40 mg plus dapoxetine 60 mg. This is a manufacturer-published product claim, not an independently authenticated package or a U.S.-approved strength. Both Super and Extra Super variants require ingredient-specific assessment; neither is interchangeable with single-agent vardenafil.
The separately listed Zhewitra Oral Jelly product describes vardenafil in a flavored jelly presentation. An online seller may market this as easier to take or faster acting, but such claims are not evidence of faster clinical onset, bioequivalence or product approval in the United States.
The FDA-approved vardenafil 10 mg ODT is a specific dissolving tablet with its own label and pharmacokinetics. A jelly sold under an India-market name cannot be assumed equivalent. See the formulation-specific ODT page for the U.S. distinction.
Sunrise marketing material describes 40 mg and 60 mg entries in the broad Zhewitra family and a specific 40 mg vardenafil plus 60 mg dapoxetine composition for Extra Super Zhewitra. These are foreign-market company claims, not standard U.S. vardenafil film-coated ED strengths or dosing recommendations. Patients must not extrapolate a clinician’s prescription from those larger marketed figures.
Any contradiction between a heading, ingredient field and physical product should be resolved through authentic documentation, not an editor’s guess. The U.S. strengths catalog records the approved product context; dose choice is a clinician’s decision.
Sunrise Remedies identifies itself as a manufacturer in product descriptions. For research purposes that supports reporting the company’s own claimed role, while a definitive statement about a particular batch should be backed by that batch’s label or other authenticated medicine documentation.
Exporter listings, white-label arrangements and third-party resellers may reproduce a corporate description without documenting the specific pack they advertise. A consistent pack insert, batch number, ingredient statement and marketing-market record provide greater confidence than a search-result caption.
FDA-approved U.S. vardenafil exists under product-specific applications. That does not grant approval to India-market Zhewitra tablets, jellies, soft variants or dapoxetine combinations. A foreign manufacturer’s references to regulatory quality do not replace verification of an actual U.S. application for the marketed product.
Personal importation of unapproved prescription drugs is generally restricted. U.S. patients should work with a licensed prescriber and pharmacy instead of relying on a foreign seller’s delivery promise. The legitimate pharmacy route describes how to verify approved dispensing.
Vardenafil has serious contraindications with nitrates and riociguat and precautions involving QT prolongation, interacting medicines and cardiovascular health. A nonstandard foreign formulation increases uncertainty about exposure and potency; a combination adds issues specific to the second ingredient.
Do not use dosage numbers on a Zhewitra marketing page to modify an existing prescription, combine ED medicines or infer a safe interaction interval. The U.S. drug-interaction overview covers the ingredient safety framework.
Record the full product name including any “Super,” “Soft,” “Jelly” or other suffix; verify each active ingredient and its labeled amount; establish whether it is a tablet or another dosage form; and document the company’s claimed role. Compare those fields with a primary manufacturer record and an authentic pack where available.
If the main product page conflicts with a product-specific listing, mark the disputed property as unresolved rather than merging descriptions. This preserves genuine brand-specific information while avoiding the appearance that every Zhewitra variant is one simple drug.
Sunrise Remedies lists Zhewitra as a vardenafil product family, but individual variants need their own ingredient and form verification.
No such broad claim is supported. Sunrise also has a separately listed oral jelly, and its family catalogue contains conflicting form descriptions.
Sunrise lists Super Zhewitra as vardenafil 20 mg plus dapoxetine 60 mg. Its broad Zhewitra page also describes Extra Super Zhewitra as vardenafil 40 mg plus dapoxetine 60 mg; both are foreign-market composition claims, not U.S.-approved monotherapy.
No. The jelly is a separate foreign-market formulation, not the specifically labeled U.S. 10 mg orally disintegrating tablet.
A separately named Sunrise vardenafil product; its exact dosage form and package details should be verified independently.
No. Such numbers appear in foreign marketing and should not be adopted as U.S. dose advice.
The brand’s foreign-market listings do not establish approval of those named products by FDA.
Do not assume equivalence or switch products independently. A U.S. clinician and pharmacist should determine an appropriate approved prescription.